This real-world study aims to evaluate the safety and efficacy of golidocitinib-based treatment regimens in patients with peripheral T-cell lymphoma (PTCL), without intervention in the selection of therapeutic strategies. A total of 1,000 PTCL patients are planned to be enrolled. After screening, eligible participants meeting the inclusion and exclusion criteria will be assigned to one of three predefined cohorts:

Cohort 1: Treatment-naïve patients with PTCL or NK/T-cell lymphoma.

Cohort 2: Patients receiving maintenance therapy following remission after first-line induction treatment for PTCL.

Cohort 3: Patients with relapsed or refractory PTCL or relapsed/refractory NK/T-cell lymphoma.

There is no cap on the number of participants in each cohort.

Inclusion Criteria:

1. Voluntarily sign and acknowledge understanding of the Informed Consent Form
2. Clinically confirmed diagnosis of peripheral T-cell lymphoma
3. Inclusion of PTCL patients who initiated a Golidocitinib-based treatment regimen within the past 3 months
4. Compliance with clinical management and provision of disease-related historical medical information required for the study, including but not limited to medical records, treatment history, and prior/prescribed therapeutic regimens

Exclusion Criteria:

1. Poor patient adherence
2. Investigator-deemed ineligibility for enrollment

Patients with peripheral T-cell lymphoma who would benefit from golicitinib